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1. Introduction
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes
is a series of Editorials, which is published on a biannual basis by the Editorial Board of the Medicinal
Chemistry section of the journal Molecules. In these Editorials, we highlight in brief reports (of about
one hundred words) a number of recently published articles that describe crucial findings, such as
the discovery of novel drug targets and mechanisms of action, or novel classes of drugs, which may
inspire future medicinal chemistry endeavours devoted to addressing prime unmet medical needs.
2. PI3Kδ Inhibition: A New Treatment Paradigm in Asthma and Chronic Obstructive
Pulmonary Disease
Highlighted by Arduino A Mangoni
Despite significant advances in diagnosis and treatment, chronic respiratory conditions such as
asthma and chronic obstructive pulmonary disease (COPD) remain a major cause of disability and
death worldwide [1]. Erra et al report the discovery and the optimization of a series of novel, inhaled,
compounds that target the phosphoinositide 3-kinase lipid kinase class I isoform δ (PI3Kδ), primarily
involved in the modulation of immune cell function [2,3]. A strategy based on the identification of
agents with high potency and selectivity towards PI3Kδ and high plasma clearance led to LAS195319,
N-[4-(4-{[(1S)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo-[2,1-f ][1,2,4]triazin-2-yl)ethyl]amino}-
7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1H-indol-6-yl]sulfamide. Pharmacokinetic studies in rat showed that
LAS195319 exhibited the highest lung exposure, both in solution and in suspension, and lung/plasma
partition ratio. In an ovalbumin-induced rat inflammation model, the intratracheal administration of
LAS195319 significantly reduced the infiltration of eosinophils and basophils in the bronchoalveolar
lavage. Notably the magnitude of these effects was similar to that of fluticasone. Pending further
pharmacological and biological characterization, the results of this study suggest that PI3Kδ might
represent a promising therapeutic target in asthma and COPD.
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3. Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on
iso-Combretastatin A-4
Highlighted by Catherine Guillou
In the past decade, the design of multi-target drugs has gained considerable interest due to their
benefits in the treatment of complex diseases such as cancer. Their design is considered as a challenge
in antitumor drug discovery. In this context, researchers from the CosMIT team (BioCIS-CNRS/UPSud
UMR 8076) have designed and synthesized dual molecules. A new series of hybrid molecules based
on isocombretastatine A-4 and belinostat was prepared. Two compounds were proven to be potent
inhibitors of both tubulin polymerization and HDAC8 activity leading to excellent antiproliferative
activity. These compounds have GI50 on HCT116 tumor cells in the nM range. They inhibit tubuline
polymerization in the µM range and HDAC8 in the nM range [4].
4. Expedient On-Resin Synthesis of Peptidic Benzimidazoles
Highlighted by Jean Jacques Vanden Eynde
The lack of new antibiotics and the spread of multi-resistant germs motivate many studies aiming
to discover specific targets that are essential for the growth of bacteria. Peptide deformylase is one of
those targets. It is a ferrous ion-containing enzyme catalyzing the removal of the N-formyl group from
N-formyl methionine during the protein synthesis. Most inhibitors are pseudopeptide hydroxamic
acids, derivatives that can be depicted as peptidomimetics bearing a chelator. Based on that scaffold
and because benzimidazoles are antibacterial agents capable of chelating Fe2+ ions, benzimidazole
conjugates containing amino acids could emerge as alternative inhibitors. Consequently, the elegant
solid phase synthesis of such conjugates, as described by Bird et al. [5], appears as an essential tool for
the design of novel innovative antibiotics.
5. Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1)
Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment
of Hypoparathyroidism
Highlighted by Christopher Hulme
PTH is an 84 amino acid polypeptide, secreted by the parathyroid glands, which maintains serum
calcium and phosphate levels through agonism of the PTH type 1 receptor (PTHR1) in bone and
kidney. The drug teriparatide (Forteo®) is a recombinant protein version of PTH consisting of the first
(N-terminus) 34 amino acids, the bioactive part of the hormone. As such, it promotes bone growth
with utility for osteoporosis. The paper herein details the discovery of a potent, orally bioavailable
small molecule PTHR1 agonist, claimed to be the precursor to the clinical candidate PCO371 being
evaluated as a treatment for hypoparathyroidism. The translation of 1-34mer peptidic agonistic activity
into a small molecule is a significant achievement [6] and if studies are directed towards osteoporosis,
the cost of goods should be significantly less than for teriparatide.
6. Prospects of Multi-Target Drugs
Highlighted by Josef Jampilek
The new broad-spectrum antibacterial chemotherapeutic 2-{[3-(3,6-dichloro-9H-carbazol-9-yl)-2-
hydroxypropyl]amino}-2-(hydroxymethyl)propane-1,3-diol (DCAP) specifically disrupts membranes
of Gram-positive and Gram-negative bacteria. In addition, it blocks autophagy by preventing
autophagolysosome maturation and interrupting the autophagic flux. Autophagy is an important
process in adaptive responses to nutrient deprivation and stress, but can be exploited by
nutrient-deprived pathogens as well as tumor cells to promote their own survival. The biological
effects of DCAP resulted in a significant reduction of uropathogenic Escherichia coli, as well as an
enhancement of the anticancer activity of the histone acetyltransferase inhibitor vorinostat that
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increases predisposition to bacterial infections [7]. Thus, DCAP belongs to so-called multi-target
agents demonstrating both antibacterial effect and anticancer adjuvant activity. Multi-target drug
discovery represents an innovative approach of medicinal chemistry that is based on the concepts
of privileged scaffolds, polypharmacology and multifactorial diseases [8]. This strategy seems to be
a very useful tool in the design of antineoplastic and anti-infectious agents, as therapeutic agents
designed in this way interact with multiple targets and thus prevent resistance acting against various
classes of pathogens and simultaneously against tumor cells [9].
7. A New Class of Vitamin D3 Analogs That Show High Cell-type Selectivity as Potential
Immunomodulatory Agents
Highlighted by Wei Li
Apart from its classical functions for mineral homeostasis, 1,25-dihydroxyvitamin D3 (1,25D3,
the biologically active form of vitamin D3) can produce important immunomodulatory effects that
could be useful for treating a variety of diseases such as osteoporosis. However, the use of 1,25D3
for effective immunomodulation is limited mainly due to hypercalcemic toxicities which presumably
arise from the activation of the vitamin D receptors (VDR) in intestine cells, instead of selective VDR
activations in immune cells. A recent report by Otero and co-workers demonstrated that by proper
modifying the sidechain, a new class of vitamin D3 analogs can achieve high cell-type selectivity for
kidney cells, bone cells, and monocytes over intestine and skin cells [10]. They further solved the
crystal structure of the best compound in complex with the VDR-ligand binding domain and revealed
the structural differences in the helix11 region and surface binding, between this compound and the
VDR native ligand 1,25D3. These results strongly suggest that it is possible to develop highly cell-type
selective VDR activators that can produce strong immunomodulatory effects without inducing the
undesired hypercalcemic toxicity.
8. Inhalable JAK1 Inhibitors for Asthma Treatment
Highlighted by Katalin Prokai-Tatrai
According to the World Health Organization, over 200 million people suffer from asthma. There
is a certain segment of asthma sufferers that do not respond well to current therapies, calling for
alternative therapeutic option. Orally bioavailable Janus kinase 1 (JAK1) inhibitors look promising
in animal models of the disease; however, they also cause significant unwanted side effects making
them unsuitable for asthma treatment in humans. Recently, a small-molecule JAK1 inhibitor of the
pyrazolopyrimidine class called iJak-381 has been reported as a novel approach to treat asthma [11].
iJak-381’s pharmacological action is highly restricted to the lungs after inhalation minimizing therefore
systemic side effects. This inhibitor is designed to be rapidly metabolized by the liver in case of
accidental systemic exposure, further improving its safety profile. The therapeutic effect of iJak-381 has
been tested in various preclinical animal models of asthma convincingly showing that lung-restricted
inhibition of JAK1 provides protection against asthma-related inflammation. This suggests that local
and selective inhibition of JAK1 has the potential to effectively and safely treat asthma in humans.
9. Prodrug Selectively Activated by Gut Enzymes Reduces Abuse
Highlighted by Jarkko Rautio
Stimulant abuse is on the rise and the marketed stimulants are vulnerable to parenteral abuse. This
paper describes a novel oral prodrug strategy to resist fencamfamine abuse by preventing intravenous
activation of its prodrugs. Prodrugs are mainly activated by pancreatic lipase that is extensively
located in the pancreas and gut but only 1% of the enzyme is found in the blood. Especially prodrugs
containing long-chain fatty acids (> C12) were resistant to intravenous but not oral hydrolysis. The C17
chain prodrug demonstrated a near complete intestinal conversion into fencamfamine and stearic
acid after oral dose to rats and no intact prodrug was detectable in plasma. In contrast, a substantial
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amount of intact prodrug was detected in the plasma following the intravenous administration. Finally,
the stearic acid prodrug of fencamfamine showed a significant oral but no intravenous increase in
locomotion. This study showed, for the first time, that a pancreatic lipase-based mechanism of prodrug
activation can address the risk of stimulant abuse. The stearic acid prodrug is being developed for the
treatment of apathy in Alzheimer’s disease and binge eating disorder [12].
10. Identification of Csf1R as Potential Anti-epileptic Therapeutic Target Applying a Novel
Computational Framework
Highlighted by Simona Collina
The identification and validation of drug target(s) still remains one of the most critical steps in
the drug discovery process. Mapping the landscape of a disease in terms of its gene regulatory
relationships offers considerable opportunities to accelerate the whole process. To address this
problem, the interdisciplinary team coordinated by Prof Michael R. Johnson [13] developed a
general computational framework that combines gene regulatory information with causal reasoning
(“Causal Reasoning Analytical Framework for Target discovery”—CRAFT). The authors proposed
this approach for the identification of cell membrane receptors with a direction-specified influence
over disease-related gene expression profiles. As proof of concept, they applied CRAFT to epilepsy
and predicted the tyrosine kinase receptor Csf1R as a potential therapeutic target. The effect of Csf1R
blockade in attenuating epilepsy seizures in three pre-clinical models of epilepsy was then validated,
confirming Csf1R as a novel therapeutic target for counteracting acquired epilepsy. Taken together,
these results highlight CRAFT as a systems-level framework for target discovery. The authors suggest
that this approach is applicable to disease settings other than epilepsy and therefore CRAFT may pave
the way for finding drugs for diseases lacking effective therapy.
11. CDK9 Inhibition as a New Tool for the Reactivation of Epigenetically Silenced Genes
in Cancer
Highlighted by Tiziano Tuccinardi
Cyclin-dependent kinase 9 (CDK9) is a member of the positive transcription elongation
factor b (P-TEFb) complex which regulates gene transcription elongation by phosphorylating the
carboxyl-terminal domain of RNA polymerase II. By using the YB5 cell-based system derived from
the human colon cancer cell line as a phenotypic screen, Issa and co-workers identified a potential
aminothiazole-based hit compound that was chemically optimized obtaining a highly selective CDK9
inhibitor (MC180295, IC50 = 5 nM) characterized by the presence of a bulky norbornyl group linked
to the 2,4-diaminothiazole central scaffold [14]. Further studies reported by the authors show that
the inhibition of CDK9 determines a reactivation of tumor-suppressor genes and increases sensitivity
to immunotherapy in cancer models. Taken together, all these data pave the way for the design and
development of new candidate drugs able to selectively inhibit CDK9.
12. Unveiling Lipid Polymorphism as a Mechanism of Membrane-Targeting Antimicrobials
Highlighted by Maria Emília Sousa
Concerning drug targets, lipids have not been as well studied as proteins. However,
regarding antibiotics, targeting bacteria cell membrane has been effective for the past 75 years.
Could the bacterial membrane still be an attractive target for new antibiotics? Rauter et al. [15]
discovered alkyl deoxy glycosides as neutral sugar-based bactericides over Gram-positive bacteria,
namely Bacillus anthracis and B. cereus. In an interdisciplinary approach combining biomolecular
simulations on phosphatidylethanolamine (PE)-rich vs. phosphatidylcholine (PC)-rich membranes,
differential metabolomics and genomics and biophysical approaches, the authors proposed
the unprecedented mode of action of these glycosides to be targeting membrane PE, thereby
promoting bacterial membrane disruption through phospholipid lamellar-to-inverted hexagonal
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phase transition. The authors disclosed this lipid polymorphism being responsible for specific
carbohydrate-phospholipid interactions and as a key factor for membrane-targeting antimicrobials.
Therefore, the bacterial membrane can be considered an attractive target, based on its essentiality,
differential arrangement from mammalian membranes, and its “resistance to resistance”.
13. Structure-Activity Relationship Study of a Social Wasp’s Venom Antimicrobial Peptide
(polybia-CP) Highlights Some “Key” Functional Motifs Allowing to Design Novel
Candidate Antibiotics
Highlighted by Jean-Marc Sabatier
The extensive use of antibiotics has favored the emergence of multidrug-resistant bacteria.
Antimicrobial peptides (AMPs) from the venoms of insects and arachnids are promising candidates
to potentially treat drug-resistant bacterial infections. Torres and collaborators [16] used a
structure-function relationship strategy in the AMP polybia-CP (Polybia paulista wasp venom) to
define its “key” functional motifs/hotspots. The helical content, net positive charge, hydrophobicity,
and hydrophobic moment were highlighted as “key” determinants of its antimicrobial potential.
The data were used to generate new AMPs with antibacterial activity in a mouse model. The approach
described, referred to as a physicochemical-guided rational design strategy to generate peptide
antibiotics, suggests that fine-tuning of such “key” parameters will enable to design nontoxic but
potent AMPs with improved broad-spectrum antibacterial properties in vitro and in vivo.
14. Nanofiber Technology: A Bioinspired Challenge for Treatment of Cancer
Highlighted by Stefania Galdiero
The development of drug nanocarriers for cancer is extremely complex. Bellat et al. [17] report on
a novel biocompatible, non-immunogenic formulation of self-assembling peptide nanofiber precursors
(NFP) characterized by a high design flexibility which allows for different lengths, charge distributions,
drugs, imaging agents, chemical moieties and functional domains. Furthermore, the optimized
glutathione (GSH)-NFP shows a unique combination of tumor uptake, penetration, infiltration,
residing and retention properties. Thus, the therapeutic and safety benefits of the formulation able to
release doxorubicin within the acidic environment of the tumor are also reported. An innovative and
fascinating approach for further developments in next generation drug nanocarriers for combination
therapies to treat cancers and infectious diseases is described. This groundbreaking paper suggests
that these combinatorial approaches are entirely feasible.
15. Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New
Ribosomal Site
Highlighted by Rafik Karaman
A new class of antibiotics has been published by researchers from the USA and France. This class,
odilorhabdins, or ODLs, is unique and promising due to the fact that its source is unconventional and
it has a unique way of killing bacteria. Therefore, it is believed that these antibacterials may be very
efficient at treating drug-resistant bacterial infections. The ODLs were produced by symbiotic bacteria
spotted in soil-dwelling nematode worms colonizing insects for food. The study revealed that ODLs
act by targeting the ribosome. However, their mechanism of action is unique because they bind to a
place on the ribosome that has never been used by other known antibiotics. The ODLs were found
to bind to the ribosome; the antibiotic disrupts the ability of the bacteria to interpret and translate
genetic code causing the ribosome to make mistakes when it creates new proteins. This miscoding
leads to corruption of the cell and causes the bacterial cell to die. The unique mechanism of ODLs is
a very strong indicator that ODLs have the potential to treat infections that are untreated by other
antibiotics [18].
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16. A Novel Role of Ceramide Synthase 1 in Fat Metabolism Has Been Defined Using a
Selective Inhibitor
Highlighted by George Kokotos
Ceramides are a family of bioactive lipids, which are involved in lipid signaling. They regulate
several physiological functions, including insulin sensitivity, and their increased levels have
been implicated in the pathogenesis of insulin resistance. In mammals, the biosynthesis
of ceramides is accomplished via the action of six different ceramide synthases (CerS1-6).
C18 ceramide, which is synthesized by ceramide synthase 1 (CerS1), has been suggested to promote
insulin resistance in humans. Recently, the discovery and characterization of the first potent,
isoform-selective CerS inhibitor, which specifically targets CerS1, has been reported [19]. P053,
(S)-2-amino-4-(4-(3,4-dichlorobenzyloxy)phenyl)-2-methylbutan-1-ol, inhibits CerS1 with nanomolar
potency, exhibiting selectivity over the other CerS isoforms, as demonstrated by lipidomic profiling.
Using this inhibitor, a role for CerS1 as an endogenous inhibitor of mitochondrial fatty acid oxidation
in muscle and regulator of whole-body adiposity has been defined. CerS1 is involved in fat metabolism
and its inhibition prevents fat deposition, but not insulin resistance induced by a high-fat diet.
17. Heparanase Inhibitor Clinical Trials
Highlighted by Giangiacomo Torri
Heparanase is a mammalian endoglycosidase that is overexpressed in various tumor forms.
The overexpression of heparanase by tumor cells is mainly correlated with their ability to form
metastases and with the vascularization of the tumor mass which ends with the reduction of survival
expectations of cancer patients also after surgical treatment. In animal models it has been observed
that non-anticoagulant heparins and their mimetics, such as sulfate oligosaccharides, inhibit the action
of heparanase, thereby becoming promising antimetastatic and antitumor drugs in various solid tumor
diseases. The inhibitory action of these drug candidates, whose chemical structure has been widely
studied, depends on the fact that they block the active site of this hydrolase mimicking the sequence
glucuronic acid β1-4 α glucosamine present in the heparan sulfates of the cell membranes. Substances
labeled with laboratory codes PI88, PG545, and M402 have passed Phase 1 clinical trials. A recent
publication reports the first trial evaluating a heparanase inhibitor in hematologic malignancies.
The results of the study on SST0001, a derivative of glycol split heparin having as its druggable target
multiple myeloma, show a safety and high tolerability profile [20].
18. Binding Kinetics Survey of the Drugged Kinome
Highlighted by F. Javier Luque
Since the introduction of the drug–target residence time model around a decade ago, increasing
attention has been paid to the lifetime of drug–target complexes to understand the activity of small
compounds [21]. Georgi and coworkers report an interesting application to kinase inhibitors [22].
To this end, the authors performed high-throughput binding kinetics assays to characterize the
interaction of 270 compounds (32 FDA-approved drugs and 238 clinical and preclinical candidates and
tool compounds) with 40 clinically-validated kinases. The results revealed that on-rates (kon) are better
correlated with dissociation constants (KD) than off-rates (koff). However, this trend was gradually
inverted with the inhibitory potency, the fraction of slowly dissociating compounds being increased
upon transition from early to late stages in drug discovery. In addition, the interplay between target
occupancy and the plasma elimination rate is critical for the efficacy profile of drugs, being relevant
for achieving kinetic selectivity between primary and potential off-targets. Finally, hydrophobic
interactions seem to play an important role in dictating the slow dissociating behavior of compounds.
Altogether, this study underscores the impact of binding kinetics in providing clues for the prospective
design of novel bioactive compounds.
Molecules 2019, 24, 130 8 of 12
19. Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem
Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study
Highlighted by M. Helena Vasconcelos
Targeting cancer stem cells (CSCs) may be an exceptional approach to prevent and treat cancer,
avoiding tumor relapse. CSCs may be responsible for tumor initiation, maintenance, metastasis,
resistance to therapeutic approaches and recurrence. However, finding specific targets and discovering
drugs that specifically target CSCs has proved a hurdle. Remarkably, different mitochondrial functions
were reported to promote acquisition and maintenance of a CSC phenotype [23], suggesting that
inhibition of mitochondrial function could be the “Achilles heel” of CSCs. This prompted novel
drug-discovery and also drug-repurposing studies, since mitochondria evolved from bacteria and
some of the currently clinically-used antibiotics target mitochondria as a side effect. The recent
publication by Scatena C. et al. [24] shows results from the first clinical pilot study using short-term
pre-operative treatment with oral doxycycline (a broad-spectrum antibiotic) to eliminate CSCs in early
breast cancer patients. Preliminary results indicate that doxycycline can reduce the expression of CD44
and ALDH1, two putative CSC markers. If confirmed, this could signify a major breakthrough in
cancer treatment, by repurposing cheap, over-the-counter antibiotics to be used together with standard
treatments, to achieve long-term survival of patients.
20. Target Validation and Identification of Novel Boronate Inhibitors of the
Plasmodium falciparum Proteasome
Highlighted by Dimitra Hadjipavlou-Litina
Malaria remains a major health problem for millions of people. The threat is increasing due
to the climatic changes on the planet. Current antimalarial therapies are highly dependent on
artemisinin-based combination therapies. Proteasome inhibitors show potential for the treatment
of malaria, exhibiting parasiticidal activity. Bortezomib, a covalent peptide boronate proteasome
inhibitor which was used clinically to treat multiple myeloma, has been shown to have activity against
P. falciparum. Tilley et al. [25] validated the β5 subunit of the proteasome as the target to generate
bortezomib-resistant parasites. A boronate peptide library was screened to identify inhibitors of
the growth of cultures of P. falciparum. It seems that inhibition of β5 activity is needed for potent
antiplasmodial activity. Amino acid residues at the P1, P2, and P3 can confer selective binding to the
P. falciparum proteasome, providing a path to further modification of the peptide boronate scaffold
in order to generate more selective inhibitors. The profiling of the substrate reveals P. falciparum 20S
proteasome active site preferences that will inform attempts to design more selective inhibitors.
21. Discovery of Novel and Powerful Antidepressants
Highlighted by Carlo Siciliano
The discovery of antidepressants is arguably the greatest breakthrough in the field of major
depression. This disorder is one of the most common, burdensome, and costly psychiatric disorders
worldwide, causing an elevated risk of suicide. Unfortunately, depression is compounded by the
lack of fast and efficacious pharmacological treatments. Antidepressants inhibit MAO-A, but they
are not selective because also MAO-B is inhibited in variable extent. These deficiencies highlight
the need for the development of novel medicaments. The discovery of the serotoninergic 5-HT7
receptor unlocked new potentialities in the clinical treatment of depression. Synthetic hydantoin
derivatives have been designed as potent and selective serotonin 5-HT7 receptor agents [26].
5-Phenyl-3-(2-hydroxy-3-(4-(2-ethoxyphenyl)piperazin-1-yl)propyl-5-methylimidazolidine-2,4-dione
was the base structure. All derivatives were easily prepared, characterized, their crystal structures
were obtained, and comprehensive investigations performed by computer-aided studies established
their structure-ligand interactions, affinities and selectivities. All hydantoin analogues showed
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potent affinities and selectivities, and their antidepressant-like effects were investigated in vivo by
behavioural tests. Aryl substituents on hydantoin and piperazine scaffolds generated powerful
antidepressants whose strong benefits on CNS were definitively assessed in silico.
22. Rational Tuning of Fluorobenzene Probes for Cysteine-Selective Protein Modification
Highlighted by Michael Gütschow
In this impressive study by Morten Meldal, Frederik Diness and their coworkers at the Center for
Evolutionary Chemical Biology, Department of Chemistry, University of Copenhagen, novel probes for
site selective cysteine labeling have been introduced [27]. The authors performed a reactivity tuning of
fluorobenzenes towards SNAr reactions with Boc-cysteine which relied on the electron withdrawing
capacity of the para substituent and on the number of fluorine substituents introduced. Optimized
probes selectively arylated cysteine residues in proteins under aqueous conditions. Chemoselective
inhibition of a cysteine protease, papain, over a serine protease, subtilisin, was also demonstrated.
Noteworthy, fluorobenzene probes allowed discrimination among cysteine residues with different
physicochemical properties in a model protein, tobacco etch virus protease. The novel probes were
successfully applied for activity-based protein profiling and for identifying proteins containing reactive
cysteine residues in cellular lysates.
23. The PROTAC Approach as a Promising Chemical Weapon in Epigenetic Modulation
Highlighted by Rino Ragno
PROTACs (proteolysis targeting chimeras) are small bi-functional molecules designed to induce
the degradation of a target protein through a proteasome-dependent mechanism [28]. In the last
decade several PROTACs have been successfully applied demonstrating to be a robust strategy to
generate potential novel therapeutics useful also for undruggable targets [29]. In particular, Bassi et al.
developed novel potential anti-inflammatory therapeutic agents by generating the first PROTACs
directed to the degradation and modulation of P300/CBP-associated factor (PCAF) and general
control nonderepressible 5 (GCN5) epigenetic proteins, containing an acetyltransferase domain and a
bromodomain [30]. Their synthesized racemic and pure enantiomers of designed PCAF PROTACs
through extensive biochemical and biological evaluation were proved to be effective in downregulating
PCAF protein levels at over 90% in macrophages and monocyte-derived dendritic cells. Data revealed
the approach to be a promising one to extend the tractability of nuclear proteins, such as epigenetic
targets, to small molecule modulation able to selectively bind to pre-defined targets. No matter what
the physiological mechanism of PROTACs could be, this strategy represents a way to develop effective
small molecule focused degraders.
24. Synthesis of New Betulinic Acid/Betulin-Derived Dimers and Hybrids with Potent
Antimalarial and Antiviral Activities
Highlighted by Paula A. C. Gomes
In tropical and sub-tropical areas of the globe, malaria is a leading cause of morbidity and
mortality, especially amongst young children. Prognosis is also very poor for people co-infected with
malaria and other pathogens, especially, retroviruses like HIV-1 or herpetic viruses, like the human
cytomegalovirus (HMCV) [31,32]. As such, any developments towards promising candidates to fight
malarial-viral co-infections are of utmost importance to tackle this tremendous health burden. In this
connection, the recent report by Tsogoeva and co-workers [33] is an important first step towards that
end. In this work, betulinic acid/betulin based dimer and hybrid compounds carrying ferrocene
and/or artesunic acid moieties displayed potent in vitro action against both P. falciparum and HCMV.
Additive and/or synergistic effects were also observed between the natural or semisynthetic products,
such as betulinic acid-/betulin- and artesunic acid-derived compounds. Overall, these are relevant
findings towards future development of effective dual-action medicines against co-infections.
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25. Small Drug TH5487 Inhibits OGG1 and Acts as Potent New Anti-inflammatory
Highlighted by Luigi A. Agrofoglio
A new small drug candidate, TH5487 [4-(4-bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-
N-(4-iodophenyl)piperidine-1-carboxamide], was reported by I. Boldogh, T. Helleday and collaborators
to be a selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) [34]. This new
compound suppresses proinflammatory gene expression and inflammation in mice. Because OGG1
binds 8-oxoG and because OGG1-deficient mice are resistant to acute and systemic inflammation,
authors hypothesized that OGG1 inhibition may represent a strategy for the prevention and treatment
of inflammation. TH5487 inhibits DNA repair by preventing OGG1 from binding to its DNA substrate
and does not affect the activity of other DNA glycosylases. This proof of concept will help in designing
small molecules that targeting oxidative DNA repair can alleviate inflammatory conditions in vivo.
26. A New Prodrug Strategy for Sulphate Containing Drugs Enables the Development of New
Oral β-Lactamase Inhibitors
Highlighted by Diego Muñoz-Torrero
Thirty-five years after launch, clavulanic acid remains the only approved oral β-lactamase
inhibitor (BLI). Diazabicyclooctanones (DBOs) are a new class of non-β-lactam BLIs but the presence
of a sulfate group in their structure precludes oral absorption, making it necessary a much less
convenient intravenous administration. Gordon et al. have developed a very elegant strategy for
the design of orally available prodrugs of the FDA-approved DBO avibactam [35]. The new prodrug
strategy combines the stability of neopentyl groups as sulfate protecting groups [36] with the metabolic
lability of an ester group placed at the end of the side chain, which upon in vivo esterase cleavage
reveals an appropriately placed nucleophile (carboxylate or alkoxide) that intramolecularly attacks
the electrophilic neopentyl methylene group, thereby expelling the active drug. The steric hindrance
exerted by the gem-dimethyl group prevents alkylation of external nucleophiles (biomolecules) while
favoring the attack of the intramolecular nucleophile by bringing it closer to the displacement site.
The novel prodrugs display high oral bioavailability in rat, dog and monkey, and in combination with
appropriate oral β-lactam antibiotics restore the antibiotic’s effectiveness.
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